Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...
Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
Alkermes Investigational Site, Overland Park, Kansas, United States
Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States
University of Bergen, Bergen, Norway
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Hospital For Special Surgery, New York, New York, United States
VA Connecticut Healthcare System - West Haven Campus, West Haven, Connecticut, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.